Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.90 -0.7%	$4.34	$3.21 ▼ $8.06	$942.67M	0.76	4.44 million shs	20,261 shs
CRVS Corvus Pharmaceuticals	$4.13 +0.1%	$3.43	$1.75 ▼ $10.00	$271.04M	0.67	736,901 shs	25,643 shs
NTLA Intellia Therapeutics	$7.80 +9.0%	$7.90	$5.90 ▼ $28.18	$796.55M	2.33	2.71 million shs	5.71 million shs
PAHC Phibro Animal Health	$24.27 -1.3%	$20.64	$16.16 ▼ $26.55	$985.18M	0.62	201,983 shs	245,008 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	+2.08%	-1.01%	-4.84%	-27.76%	-43.21%
CRVS Corvus Pharmaceuticals	+2.23%	+12.26%	+13.81%	-0.24%	+86.43%
NTLA Intellia Therapeutics	+7.40%	-17.49%	-13.01%	-17.84%	-67.30%
PAHC Phibro Animal Health	-1.06%	-0.57%	+24.85%	+3.45%	+35.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.6136 of 5 stars	4.5	3.0	0.0	4.4	2.1	2.5	0.6
CRVS Corvus Pharmaceuticals	2.1692 of 5 stars	3.5	1.0	0.0	0.0	2.1	2.5	0.6
NTLA Intellia Therapeutics	4.6307 of 5 stars	4.3	1.0	0.0	4.7	3.1	2.5	1.3
PAHC Phibro Animal Health	3.7518 of 5 stars	0.8	3.0	2.5	1.1	3.6	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.90	Moderate Buy	$10.39	166.25% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	263.64% Upside
NTLA Intellia Therapeutics	2.67	Moderate Buy	$34.95	348.02% Upside
PAHC Phibro Animal Health	1.50	Reduce	$20.00	-17.59% Downside

Current Analyst Ratings Breakdown

Latest CRVS, ARDX, NTLA, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00
5/12/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $45.00
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
5/9/2025	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $10.00
5/9/2025	NTLA Intellia Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$68.00 ➝ $68.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00

(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$361.71M	2.58	N/A	N/A	$0.73 per share	5.35
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.79 per share	N/A
NTLA Intellia Therapeutics	$45.57M	17.73	N/A	N/A	$11.73 per share	0.67
PAHC Phibro Animal Health	$1.19B	0.83	$2.23 per share	10.87	$6.09 per share	3.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.22	N/A	12.59	N/A	-11.73%	-24.87%	-10.51%	7/30/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$27.03M	-$0.98	N/A	N/A	N/A	N/A	-70.71%	-45.90%	8/5/2025 (Estimated)
NTLA Intellia Therapeutics	-$481.19M	-$5.23	N/A	N/A	N/A	N/A	-49.34%	-40.27%	8/14/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	50.64	11.56	0.45	1.75%	25.35%	6.21%	N/A

Latest CRVS, ARDX, NTLA, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million
3/25/2025	Q4 2024	CRVS Corvus Pharmaceuticals	-$0.12	-$0.18	-$0.06	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.98%	N/A	61.54%	N/A

Latest CRVS, ARDX, NTLA, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	0.87	4.58	4.31
CRVS Corvus Pharmaceuticals	N/A	0.92	0.92
NTLA Intellia Therapeutics	N/A	6.73	6.73
PAHC Phibro Animal Health	2.99	3.20	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
CRVS Corvus Pharmaceuticals	46.64%
NTLA Intellia Therapeutics	88.77%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
CRVS Corvus Pharmaceuticals	28.50%
NTLA Intellia Therapeutics	3.10%
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	239.26 million	222.88 million	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	44.15 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	98.59 million	Optionable
PAHC Phibro Animal Health	1,860	40.53 million	20.22 million	Optionable

CRVS, ARDX, NTLA, and PAHC Headlines

Recent News About These Companies

Mackenzie Financial Corp Acquires New Holdings in Phibro Animal Health Co. (NASDAQ:PAHC)

June 4 at 4:13 AM | marketbeat.com

3 Stocks Showing Positive Momentum Despite Trade Tensions

June 3 at 4:00 PM | zacks.com

Summit Global Investments Has $811,000 Stake in Phibro Animal Health Co. (NASDAQ:PAHC)

June 1 at 6:08 AM | marketbeat.com

Ameriprise Financial Inc. Purchases 21,576 Shares of Phibro Animal Health Co. (NASDAQ:PAHC)

June 1 at 3:19 AM | marketbeat.com

Jane Street Group LLC Trims Stock Position in Phibro Animal Health Co. (NASDAQ:PAHC)

June 1 at 3:19 AM | marketbeat.com

Kings Path Partners LLC Buys New Stake in Phibro Animal Health Co. (NASDAQ:PAHC)

May 31, 2025 | marketbeat.com

Millennium Management LLC Has $4.36 Million Position in Phibro Animal Health Co. (NASDAQ:PAHC)

May 31, 2025 | marketbeat.com

Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock

May 29, 2025 | zacks.com

Phibro (PAHC) is an Incredible Growth Stock: 3 Reasons Why

May 28, 2025 | zacks.com

PAHC or BSX: Which Is the Better Value Stock Right Now?

May 28, 2025 | zacks.com

Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?

May 28, 2025 | zacks.com

Man Group plc Purchases Shares of 23,836 Phibro Animal Health Co. (NASDAQ:PAHC)

May 28, 2025 | marketbeat.com

Phibro Animal Health Co. (NASDAQ:PAHC) Shares Purchased by Nuveen Asset Management LLC

May 28, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Trims Stock Holdings in Phibro Animal Health Co. (NASDAQ:PAHC)

May 28, 2025 | marketbeat.com

Research Analysts Issue Forecasts for PAHC FY2025 Earnings

May 27, 2025 | marketbeat.com

Research Analysts Set Expectations for PAHC FY2025 Earnings

May 25, 2025 | marketbeat.com

Zacks Research Has Bullish Outlook for PAHC FY2025 Earnings

May 25, 2025 | americanbankingnews.com

4 Stocks Trading Near 52-Week High With Room to Rise Further

May 23, 2025 | zacks.com

Best Growth Stocks to Buy for May 23rd

May 23, 2025 | zacks.com

Best Value Stocks to Buy for May 23rd

May 23, 2025 | zacks.com

Best Income Stocks to Buy for May 23rd

May 23, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, ARDX, NTLA, and PAHC Company Descriptions

Ardelyx NASDAQ:ARDX

$3.90 -0.03 (-0.71%)

As of 09:36 AM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$4.12 +0.01 (+0.12%)

As of 09:36 AM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Intellia Therapeutics NASDAQ:NTLA

$7.80 +0.64 (+8.95%)

As of 09:36 AM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$24.27 -0.31 (-1.26%)

As of 09:35 AM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time